NEW YORK (GenomeWeb) – Gene editing firm Homology Medicines announced yesterday that it has raised $83.5 million in a Series B funding round.

The round was led by Deerfield Management, and new investors included Fidelity Management and Research Company, HBM Healthcare Investments, Maverick Ventures, Novartis, Rock Springs Capital, Vida Ventures, Vivo Capital, and Alexandria Venture Investments. Existing investors 5AM Ventures, ARCH Venture Partners and Temasek also participated in the financing.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.